Please login to the form below

Not currently logged in
Email:
Password:

Cimzia

This page shows the latest Cimzia news and features for those working in and with pharma, biotech and healthcare.

UCB looks to pipeline with five years left for twin blockbusters

UCB looks to pipeline with five years left for twin blockbusters

Vimpat is forecast to reach 1.4bn by 2022, the year its US patent expires, with Cimzia is expected to reach 1.7bn when it faces the same fate in 2024. ... next five years before Cimzia goes off patent.

Latest news

  • FCB Health Europe takes aim at strategy development FCB Health Europe takes aim at strategy development

    From there, Huzzey moved to UCB Biopharma in Belgium, where she worked initially as European brand lead for CIMZIA, before taking on a role in the UK as head of country

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

  • NICE approves UCB Pharma’s Cimzia NICE approves UCB Pharma’s Cimzia

    But this new guidance significantly extends the number of patients who could now be eligible for Cimzia, which is already a star performer for UCB. ... Cimzia works by stopping the body's immune system attacking the joints - this in turn helps to reduce

  • NICE set to recommend seven biologics for severe rheumatoid arthritis NICE set to recommend seven biologics for severe rheumatoid arthritis

    NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Specifically Cimzia, one of

More from news
Approximately 7 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • Investing in the future of R&D Investing in the future of R&D

    Funding growth . Looking to his company's current performance, Doliveux says UCB is now in “an intense growth phase fuelled by Cimzia”.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • Pharma deals during July 2014 Pharma deals during July 2014

    Acknowledging the importance of therapeutic area expertise and in an innovative deal to expand the application of Cimzia outside its current indications, UCB has granted an exclusive licence to US-based ... dermatology specialist Dermira to develop

  • Pharma deals during November 2013 Pharma deals during November 2013

    Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics